Background: Four distinct familial types of isolated GH deficiency (IGHD) have been described so far.
Objective: We report a novel nonsense GH1 mutation in a father and a son.
Patients: Father's height was 137.3 cm (-6.79 SDS); mother's height was 157.3 cm (-1.86 SDS). By the age of 8.25 years, his height was 104.3 cm (-4.82 SDS) and his weight was 18.3 kg (-3.35 SDS). GH stimulation tests had low peak GH value of 6.5 ng/ml (proband) and 6.3 ng/ml (father). Other pituitary hormones and magnetic resonance imaging (MRI) of the pituitary region was normal in both patients. The proband received recombinant human GH (rhGH) treatment (30 μg/kg/day) and he grew 15.4 cm in 15 months.
Results: Sequencing of the GH1 gene revealed a novel heterozygous nonsense mutation in both the father and the son (c.199A>T), which introduces a stop codon in exon 3.
Conclusion: We present a family with IGHD II, with severe short stature, no phenotypic characteristics of GHD and a novel nonsense mutation in exon 3 of the GH1 gene. As fibroblasts were unavailable, we used computer analysis and we propose a unique mechanism that combines aberrant splicing and derogated GH release from the pituitary with residual secretion of a bioinactive truncated GH peptide.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000334643 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic variations, clinical presentation and treatment outcome of isolated growth hormone deficiency type I and II: case series and review of the literature.
Endocrine
November 2024
Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730, Beijing, China.
Article Synopsis
- A study reported on four patients with isolated growth hormone deficiency (IGHD) type I from two Chinese families, analyzing the genetic mutations involved and their effects on growth.
- Whole exome sequencing identified a novel mutation in the GH1 gene and deletions in another patient pedigree, both leading to significant growth delays but ultimately positive responses to growth hormone therapy.
- A literature review highlighted differences between IGHD type I and II, showing that type I patients generally present at a younger age with more severe symptoms, and that early diagnosis is linked to better treatment outcomes.
The clinical and genetic aspects of six individuals with variants and isolated growth hormone deficiency type II.
Front Endocrinol (Lausanne)
October 2024
Department of Endocrinology, Genetics and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian, ;China.
Article Synopsis
- Isolated growth hormone deficiency type II (IGHD II) is a genetic condition leading to low growth hormone production, resulting in stunted growth and lower IGF-1 levels in affected individuals.
- The study examined six children from Chinese families with IGHD II, revealing various genetic variants associated with the condition, including several novel mutations.
- After starting growth hormone replacement therapy, the children showed significant improvement in height, with an average increase of 1.21 SDS in the first six months and 1.79 SDS in the first year of treatment.
Rational Engineering of a β-Glucosidase (H0HC94) from Glycosyl Hydrolase Family I (GH1) to Improve Catalytic Performance on Cellobiose.
J Phys Chem B
September 2024
Protein Engineering Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal 741246, India.
The conversion of lignocellulosic feedstocks by cellulases to glucose is a critical step in biofuel production. β-Glucosidases catalyze the final step in cellulose breakdown, producing glucose, and are often the rate-limiting step in biomass hydrolysis. The specific activity of most natural and engineered β-glucosidase is higher on the artificial substrate -nitrophenyl β-d-glucopyranoside (NPGlc) than on the natural substrate, cellobiose.
View Article and Find Full Text PDFNkd1 functions downstream of Axin2 to attenuate Wnt signaling.
Mol Biol Cell
July 2024
Department of Molecular and Cellular Biology, University of Guelph, Guelph, N1G 2W1 Ontario, Canada.
Wnt signaling is a crucial developmental pathway involved in early development as well as stem-cell maintenance in adults and its misregulation leads to numerous diseases. Thus, understanding the regulation of this pathway becomes vitally important. Axin2 and Nkd1 are widely utilized negative feedback regulators in Wnt signaling where Axin2 functions to destabilize cytoplasmic β-catenin, and Nkd1 functions to inhibit the nuclear localization of β-catenin.
View Article and Find Full Text PDFConstruction and validation of a RARRES3-based prognostic signature related to the specific immune microenvironment of pancreatic cancer.
Front Oncol
February 2024
Cancer Institute, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Background: Tumor immune microenvironment (TiME) is prognostically instructive in Pancreatic adenocarcinoma (PAAD). However, the potential value of TiME-related genes in the individualized immunotherapy of PAAD has not been clarified.
Methods: Correlation between Immune-Related Genes (IRGs) and immune-related transcription factors (TFs) was performed to prove the immune correlation of selected genes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!